X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SYT-510 is a first-in-class inhibitor that modulates a newly identified drug target in the Endocannabinoid System to restore healthy brain physiology. It is being evaluated in preclinical studies for anxiety, post-traumatic stress disorder & mood-related diseases.
Lead Product(s): SYT-510
Therapeutic Area: Psychiatry/Psychology Product Name: SYT-510
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
This investment brings total Series A financing to CHF 24 million to complete pre-clinical development and progress lead candidate through proof-of-concept clinical studies. Synendos is advancing the preclinical and clinical development of SYT-510.
Lead Product(s): SYT-510
Therapeutic Area: Psychiatry/Psychology Product Name: SYT-510
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ysios Capital
Deal Size: $26.6 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 20, 2021
Details:
Financing will allow Synendos Therapeutics to complete pre-clinical development and progress lead candidate through proof of concept clinical study.
Lead Product(s): SYT-510
Therapeutic Area: Neurology Product Name: SYT-510
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kurma Partners
Deal Size: $22.4 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
